Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05983965Phase 1Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat in peripheral T-cell lymphoma (PTCL), sponsored by University of Alabama at Birmingham. Primary endpoint: Recommended Phase II Dose at 28 days. Started Sep 2024; status: terminated.
02
Drugs
tazemetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05983965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983965.